Bio-Techne Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Bio-Techne sono diminuiti a un tasso medio annuo di -14.4%, mentre il settore Life Sciences ha visto gli utili diminuire a un tasso medio annuo di 3.8%. I ricavi sono cresciuti crescere a un tasso medio annuo di 5.1%. Il ritorno sul capitale proprio di Bio-Techne è 5.3% e ha margini netti di 9%.
Informazioni chiave
-14.40%
Tasso di crescita degli utili
-14.60%
Tasso di crescita dell'EPS
| Life Sciences Crescita del settore | 21.51% |
| Tasso di crescita dei ricavi | 5.12% |
| Rendimento del capitale proprio | 5.25% |
| Margine netto | 9.04% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento dell'analisi • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.Aggiornamento dell'analisi • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).Aggiornamento dell'analisi • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).Aggiornamento dell'analisi • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).
Aggiornamento dell'analisi • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.Articolo di analisi • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...Aggiornamento dell'analisi • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).Aggiornamento dell'analisi • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking AlphaAggiornamento dell'analisi • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).Aggiornamento dell'analisi • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).Aggiornamento dell'analisi • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.Aggiornamento dell'analisi • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).Articolo di analisi • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...Aggiornamento dell'analisi • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.Aggiornamento dell'analisi • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.Aggiornamento dell'analisi • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Articolo di analisi • Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation's ( NASDAQ:TECH ) price-to-earnings (or "P/E") ratio of 70x might make it look like a strong...Articolo di analisi • May 29
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
Bio-Techne Corporation ( NASDAQ:TECH ), might not be a large cap stock, but it saw significant share price movement...Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alpha
Nuova analisi • Aug 22
Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges
Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Bio-Techne guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 1,211 | 109 | 397 | 97 |
| 31 Dec 25 | 1,216 | 81 | 441 | 98 |
| 30 Sep 25 | 1,217 | 78 | 450 | 100 |
| 30 Jun 25 | 1,220 | 73 | 446 | 99 |
| 31 Mar 25 | 1,209 | 132 | 495 | 92 |
| 31 Dec 24 | 1,196 | 158 | 452 | 99 |
| 30 Sep 24 | 1,172 | 151 | 435 | 97 |
| 30 Jun 24 | 1,159 | 168 | 429 | 97 |
| 31 Mar 24 | 1,154 | 203 | 417 | 102 |
| 31 Dec 23 | 1,145 | 224 | 426 | 93 |
| 30 Sep 23 | 1,144 | 247 | 407 | 93 |
| 30 Jun 23 | 1,137 | 285 | 397 | 92 |
| 31 Mar 23 | 1,124 | 271 | 415 | 92 |
| 31 Dec 22 | 1,120 | 262 | 390 | 91 |
| 30 Sep 22 | 1,118 | 292 | 400 | 89 |
| 30 Jun 22 | 1,106 | 272 | 392 | 87 |
| 31 Mar 22 | 1,076 | 225 | 361 | 85 |
| 31 Dec 21 | 1,030 | 210 | 350 | 80 |
| 30 Sep 21 | 985 | 177 | 334 | 76 |
| 30 Jun 21 | 931 | 140 | 312 | 71 |
| 31 Mar 21 | 848 | 184 | 296 | 67 |
| 31 Dec 20 | 799 | 175 | 282 | 66 |
| 30 Sep 20 | 760 | 248 | 271 | 65 |
| 30 Jun 20 | 739 | 229 | 267 | 65 |
| 31 Mar 20 | 755 | 187 | 273 | 65 |
| 31 Dec 19 | 745 | 195 | 271 | 64 |
| 30 Sep 19 | 734 | 93 | 266 | 64 |
| 30 Jun 19 | 714 | 96 | 262 | 62 |
| 31 Mar 19 | 703 | 121 | 257 | 60 |
| 31 Dec 18 | 682 | 96 | 244 | 58 |
| 30 Sep 18 | 661 | 128 | 232 | 57 |
| 30 Jun 18 | 643 | 126 | 216 | 55 |
| 31 Mar 18 | 619 | 112 | 194 | 55 |
| 31 Dec 17 | 599 | 114 | 187 | 55 |
| 30 Sep 17 | 577 | 73 | 183 | 54 |
| 30 Jun 17 | 563 | 76 | 175 | 54 |
| 31 Mar 17 | 541 | 74 | 170 | 51 |
| 31 Dec 16 | 528 | 82 | 158 | 49 |
| 30 Sep 16 | 517 | 101 | 145 | 47 |
| 30 Jun 16 | 499 | 104 | 138 | 45 |
| 31 Mar 16 | 482 | 105 | 130 | 44 |
| 31 Dec 15 | 465 | 99 | 125 | 44 |
| 30 Sep 15 | 456 | 107 | 121 | 43 |
| 30 Jun 15 | 452 | 108 | 115 | 41 |
Guadagni di qualità: TECH ha un grande una tantum perdita di $157.0M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 31st March, 2026.
Margine di profitto in crescita: Gli attuali margini di profitto netti di TECH (9%) sono inferiori rispetto allo scorso anno (10.9%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di TECH sono diminuiti del 14.4% all'anno negli ultimi 5 anni.
Accelerare la crescita: TECH ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.
Guadagni vs Settore: TECH ha avuto una crescita negativa degli utili ( -16.8% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Life Sciences ( 3.8% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 5.3% ) di TECH è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/11 08:38 |
| Prezzo dell'azione a fine giornata | 2026/05/11 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Bio-Techne Corporation è coperta da 25 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |